In this paper, we propose a new architecture that combines prediction and decision-making in the form of a hybrid framework aimed at providing clinicians with transparent and accurate maps, or charts, to guide and to ...In this paper, we propose a new architecture that combines prediction and decision-making in the form of a hybrid framework aimed at providing clinicians with transparent and accurate maps, or charts, to guide and to support treatment decisions, and to interrogate the clinical patients’ course as it develops. These maps should be patient-specific, with options displayed of possible treatment pathways. They would suggest the optimal care pathways, and the shortest routes to the most efficient care, by predicting clinical progress, testing the ensuing suggestions against the developing clinical state and patient condition, and suggesting new options as necessary. These maps should also mine an extensive database of accumulated patient data, modelled diseases, and modelled patient-responses based on expert-derived rules. These individualized hierarchical targets, which are implemented in order to prevent life-threatening illnesses, will also have to “adapt” to the patient’s altering clinical condition. Therapies that support one system can destabilize others and selecting which specific support to prioritize is an uncertain process, the prioritization of which can vary between clinical experts. Whilst clinical therapeutic decisions can be made with some degree of anticipation of the “likely” outcome (based on the experts’ opinion and judgment), treatment is essentially rooted in the present, and is dependent on analyzing the current clinical condition and available data. The recursive learning approach presented in this paper, allows decision rules to predict the possible future course, and reflects back derived information from such projections to the present time and thus support proactive clinical care rather than reactive clinical care. The proposed framework for such a patient map supports and enables an optimized choice from available options and also ensures that decisions are based on both the available evidence and a database of best clinical practice. Preliminary results are encouraging and i展开更多
China has been undertaking a profound reform on health care.Although more than 1.16 billion people have been covered by rural and urban medical insurance to date,the level of reimbursement from insurance is very limit...China has been undertaking a profound reform on health care.Although more than 1.16 billion people have been covered by rural and urban medical insurance to date,the level of reimbursement from insurance is very limited,especially for critical diseases such as leukemia.This places heavy economic burdens on patients.Under these circumstances,systems innovation is imperative for the efficient utilization of limited funding.In this respect,certain valuable experience from other countries may prove helpful.The prospective payment system of Diagnosis-related Groups(DRGs),Clinical Paths,and the Comparative Effectiveness Analysis adopted by the National Institute of Health and Clinical Excellence(NICE,UK),can befine tools to reduce medical costs and improve quality of services.Treatments of acute promyelocytic leukemia at Rui-Jin Hospital,and childhood acute lymphoblastic leukemia at Shanghai Children’s Medical Center,can be taken as suitable models to illustrate the crucial role of Clinical Paths in guaranteeing clinical and cost effectiveness of medical services for critical diseases,and to satisfactorily justify the feasibility of DRGs in China.展开更多
文摘In this paper, we propose a new architecture that combines prediction and decision-making in the form of a hybrid framework aimed at providing clinicians with transparent and accurate maps, or charts, to guide and to support treatment decisions, and to interrogate the clinical patients’ course as it develops. These maps should be patient-specific, with options displayed of possible treatment pathways. They would suggest the optimal care pathways, and the shortest routes to the most efficient care, by predicting clinical progress, testing the ensuing suggestions against the developing clinical state and patient condition, and suggesting new options as necessary. These maps should also mine an extensive database of accumulated patient data, modelled diseases, and modelled patient-responses based on expert-derived rules. These individualized hierarchical targets, which are implemented in order to prevent life-threatening illnesses, will also have to “adapt” to the patient’s altering clinical condition. Therapies that support one system can destabilize others and selecting which specific support to prioritize is an uncertain process, the prioritization of which can vary between clinical experts. Whilst clinical therapeutic decisions can be made with some degree of anticipation of the “likely” outcome (based on the experts’ opinion and judgment), treatment is essentially rooted in the present, and is dependent on analyzing the current clinical condition and available data. The recursive learning approach presented in this paper, allows decision rules to predict the possible future course, and reflects back derived information from such projections to the present time and thus support proactive clinical care rather than reactive clinical care. The proposed framework for such a patient map supports and enables an optimized choice from available options and also ensures that decisions are based on both the available evidence and a database of best clinical practice. Preliminary results are encouraging and i
基金supported in part by the Program of Improving Health Services in China’s Rural Areas supported by the World Bank Loans(Qinghai Province,QHWST-2009KT01).
文摘China has been undertaking a profound reform on health care.Although more than 1.16 billion people have been covered by rural and urban medical insurance to date,the level of reimbursement from insurance is very limited,especially for critical diseases such as leukemia.This places heavy economic burdens on patients.Under these circumstances,systems innovation is imperative for the efficient utilization of limited funding.In this respect,certain valuable experience from other countries may prove helpful.The prospective payment system of Diagnosis-related Groups(DRGs),Clinical Paths,and the Comparative Effectiveness Analysis adopted by the National Institute of Health and Clinical Excellence(NICE,UK),can befine tools to reduce medical costs and improve quality of services.Treatments of acute promyelocytic leukemia at Rui-Jin Hospital,and childhood acute lymphoblastic leukemia at Shanghai Children’s Medical Center,can be taken as suitable models to illustrate the crucial role of Clinical Paths in guaranteeing clinical and cost effectiveness of medical services for critical diseases,and to satisfactorily justify the feasibility of DRGs in China.
